FibroBiologics Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Listing Compliance

FibroBiologics has announced a 1-for-20 reverse stock split to regain compliance with Nasdaq's bid price requirement. The reverse split will reduce outstanding shares from 70 million to approximately 3.5 million and is expected to become effective on March 30, 2026. The company's board of directors approved the move to broaden investor interest and maintain listing on The Nasdaq Capital Market.